These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 5778632)

  • 1. Specific chelation therapy with desferrioxamine in massive iron overdose.
    Levison LH
    Appl Ther; 1969 Mar; 11(3):153. PubMed ID: 5778632
    [No Abstract]   [Full Text] [Related]  

  • 2. Management of acute iron overdose.
    Mann KV; Picciotti MA; Spevack TA; Durbin DR
    Clin Pharm; 1989 Jun; 8(6):428-40. PubMed ID: 2663331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute respiratory distress syndrome in children with acute iron poisoning: the role of intravenous desferrioxamine.
    Ioannides AS; Panisello JM
    Eur J Pediatr; 2000 Mar; 159(3):158-9. PubMed ID: 10664227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucose tolerance and chelation therapy in patients with thalassaemia major.
    Capra L; Atti G; De Sanctis V; Candini G
    Haematologica; 1983; 68(1):63-8. PubMed ID: 6404709
    [No Abstract]   [Full Text] [Related]  

  • 5. Aluminum intoxication in a child: treatment with intraperitoneal desferrioxamine.
    Warady BA; Ford DM; Gaston CE; Sedman AB; Huffer WE; Lum GM
    Pediatrics; 1986 Oct; 78(4):651-5. PubMed ID: 3763276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
    Giardina PJ; Grady RW
    Semin Hematol; 1995 Oct; 32(4):304-12. PubMed ID: 8560288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of desferrioxamine B and 2-(beta-aminoethoxy)cyclohexylaminetetraacetate in experimental hemochromatosis in rats and in primary hemochromatosis of man].
    Bohne F; Lessmann J
    Arzneimittelforschung; 1969 Jun; 19(6):944-7. PubMed ID: 5820039
    [No Abstract]   [Full Text] [Related]  

  • 8. Iron metabolism and chelation therapy in hemosiderosis.
    Graziano JH
    Curr Top Hematol; 1978; 1():127-50. PubMed ID: 400529
    [No Abstract]   [Full Text] [Related]  

  • 9. Pediatric iron overload.
    Cohen AR
    Clin Adv Hematol Oncol; 2007 Aug; 5(8):601-2. PubMed ID: 17982399
    [No Abstract]   [Full Text] [Related]  

  • 10. Deferoxamine as a chelating agent.
    Westlin WF
    Clin Toxicol; 1971 Dec; 4(4):597-602. PubMed ID: 5164172
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of transfusional iron overload.
    Cohen A
    Am J Pediatr Hematol Oncol; 1990; 12(1):4-8. PubMed ID: 2178459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload.
    Borgna-Pignatti C; Franchini M; Gandini G; Vassanelli A; De Gironcoli M; Aprili G
    Haematologica; 1998 Sep; 83(9):788-90. PubMed ID: 9825575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Whole bowel irrigation in infants for acute iron poisoning].
    Sokolover N; Rachmel A
    Harefuah; 2000 May; 138(10):837-41, 910. PubMed ID: 10883250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The use of desferrioxamine in iron poisoning and hemosiderosis].
    Karlsson B; Lagercrantz R; Brann I; Strandberg O; Reizenstein P
    Nord Med; 1965 Oct; 74(40):985-8. PubMed ID: 5836665
    [No Abstract]   [Full Text] [Related]  

  • 15. Chelators at the cancer coalface: desferrioxamine to Triapine and beyond.
    Yu Y; Wong J; Lovejoy DB; Kalinowski DS; Richardson DR
    Clin Cancer Res; 2006 Dec; 12(23):6876-83. PubMed ID: 17145804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A case of acute iron poisoning. Contribution on the therapy of acute iron poisoning with the iron complex constituent desferrioxamine B].
    Scherzinger F
    Monatsschr Kinderheilkd (1902); 1966 Dec; 114(12):596-7. PubMed ID: 5998613
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of acute iron intoxication with deferoxamine: a report of six cases. Chelating agent proves effective in management of acute iron poisoning.
    Coli RD; Leone LA; Albala MM
    R I Med J; 1967 Aug; 50(8):549-53 passim. PubMed ID: 5235587
    [No Abstract]   [Full Text] [Related]  

  • 18. Desferrioxamine-chelatable iron (DCI), a component of serum non-transferrin-bound iron (NTBI) used for assessing iron chelation therapy.
    Breuer W; Ermers MJ; Pootrakul P; Abramov A; Hershko C; Cabantchik ZI
    Transfus Sci; 2000 Dec; 23(3):241-2. PubMed ID: 11099901
    [No Abstract]   [Full Text] [Related]  

  • 19. Studies in acute iron poisoning. I. Desferrioxamine in the treatment of acute iron poisoning: clinical observations, experimental studies, and theoretical considerations.
    Whitten CF; Gibson GW; Good MH; Goodwin JF; Brough AJ
    Pediatrics; 1965 Sep; 36(3):322-35. PubMed ID: 5829325
    [No Abstract]   [Full Text] [Related]  

  • 20. Iron excretion in thalassemia after the administration of chelating agents.
    Markum AH; Iskandar W; Keng KL; Odang O
    Paediatr Indones; 1969; 9(3):89-98. PubMed ID: 4981722
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.